Business
Fractyl Health Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference and the German Diabetes Association (DDG) Annual Meeting
At DDG, Fractyl Health will present new clinical updates on its ongoing real-world registry study of Revita® in patients with T2D in Germany At DDW, Fractyl
About this update from Fractyl Health, Inc.
[{"type":"text","content":"At DDG, Fractyl Health will present new clinical updates on its ongoing real-world registry study of Revita® in patients with T2D in Germany At DDW, Fractyl Health will provide an oral presentation from its Rejuva® platform with new preclinical data demonstrating the potential of GLP-1 based pancreatic gene therapy (GLP-1 PGTx) to durably reduce liver fat in the diet-induced obesity model BURLINGTON, Mass., April 30, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches for the treatment of obesity and type 2 diabetes (T2D), today announced that it will present new data from its ongoing real-world registry study of Revita for T2D at the upcoming German Diabetes Association (DDG) Annual Meeting taking place May 8-11, 2024, in Berlin, Germany. The Company will also present an oral abstract with new preclinical data on the potential of Rejuva to durably impact liver metabolic health during the 2024 Digestive Disease Week (DDW) taking place May 18-24, 2024, in Washington, D.C. Details of the presentations are provided below. German Diabetes Association (DDG) Annual Meeting Presentation Title: A Prospective Post-Market Clinical Follow-Up Registry to Evaluate Real-World Effectiveness of Duodenal Mucosal Resurfacing in Patients with Type 2 DiabetesPoster Number: P01.02 (Paper-ID: 68228)Poster Area: Posterwalk 1: Prediabetes and Type 2 Diabetes (Clinical)Location: Level 1 – Poster AreaPresentation Date & Time: Thursday, May 9, 2024, from 2:07 p.m. – 2:14 p.m. ET Digestive Disease Week (DDW) Presentation Title: Single-Dose GLP-1-Based Pancreatic Gene Therapy Maintains Weight Loss After Semaglutide Withdrawal and Reduces Hepatic Triglycerides in a Murine Model of ObesityAbstract Number: 4029196Session Title: AGA Basic Science PlenaryLocation: 103AB at the Walter E. Washington Convention CenterPresentation Date & Time: Sunday, May 19, 2024, from 4:00 p.m. - 5:30 p.m. ET About Fractyl Health Fractyl Health is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including obesity and T2D. Despite advances in treatment over the last 50 years, obesity and TD2 continue to be rapidly growing drivers of morbidity and mortality in the 21st century. Fractyl Health’s goal is to transform metabolic dis...